RNA Overview

Atrium Therapeutics, Inc. is a biopharmaceutical company engaged in the delivery of ribonucleic acid (RNA) therapeutics for people living with cardiomyopathy. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. It is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.

Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is75.63 USD with a low forecast of 72.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Atrium Therapeutics Inc revenue for the last quarter amounts to 859.00K USD, decreased -71.11

Atrium Therapeutics Inc. EPS for the last quarter amounts to -1.70 USD, increased 153.73

Atrium Therapeutics Inc (RNA) has 47 emplpoyees as of April 01 2026.

Today RNA has the market capitalization of 207.44M USD.